Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Summit Therapeutics (SMMT) Intangibles: 2016-2022

Historic Intangibles for Summit Therapeutics (SMMT) over the last 6 years, with Sep 2022 value amounting to $8.0 million.

  • Summit Therapeutics' Intangibles fell 25.04% to $8.0 million in Q3 2022 from the same period last year, while for Sep 2022 it was $8.0 million, marking a year-over-year decrease of 25.04%. This contributed to the annual value of $10.4 million for FY2021, which is 9.69% down from last year.
  • According to the latest figures from Q3 2022, Summit Therapeutics' Intangibles is $8.0 million, which was down 10.65% from $8.9 million recorded in Q2 2022.
  • Over the past 5 years, Summit Therapeutics' Intangibles peaked at $13.9 million during Q1 2019, and registered a low of -$159,000 during Q1 2020.
  • For the 3-year period, Summit Therapeutics' Intangibles averaged around $9.3 million, with its median value being $10.5 million (2021).
  • Its Intangibles has fluctuated over the past 5 years, first spiked by 195,889.47% in 2019, then declined by 25.04% in 2022.
  • Summit Therapeutics' Intangibles (Quarterly) stood at -$6,493 in 2018, then surged by 192,344.59% to $13.1 million in 2019, then declined by 12.23% to $11.5 million in 2020, then decreased by 9.69% to $10.4 million in 2021, then fell by 25.04% to $8.0 million in 2022.
  • Its Intangibles was $8.0 million in Q3 2022, compared to $8.9 million in Q2 2022 and $9.9 million in Q1 2022.